Autoimmune diseases are common conditions characterized by loss of tolerance, female predominance and a remarkable heterogeneity among different populations. Most often they are polygenic and several genetic loci have been linked with the risk of developing autoimmune diseases. However, causal inference is difficult. When the genomic revolution began there were high hopes of translating fast genetic analyses to the bedside but this has proven to be challenging. Nonetheless, over the last decade, fine-mapping strategies have greatly improved; one of the most significant research lines focuses on the in vivo and ex vivo definition of the effect of genetic variants within the target tissues and within specific subpopulations of immune cells that are involved in the disease pathogenesis. This strategy also includes the longitudinal tracking of a large number of immunophenotypes in many individuals to build a large reference atlas for variant characterization. In this review, we discuss the results obtained by GWAS in autoimmune diseases and review recent advances in fine mapping strategies. More importantly, we discuss gaps and future directions.

Gerussi, A., Soskic, B., Asselta, R., Invernizzi, P., Gershwin, M. (2022). GWAS and autoimmunity: What have we learned and what next. JOURNAL OF AUTOIMMUNITY, 133(December 2022) [10.1016/j.jaut.2022.102922].

GWAS and autoimmunity: What have we learned and what next

Gerussi A.
;
Invernizzi P.;
2022

Abstract

Autoimmune diseases are common conditions characterized by loss of tolerance, female predominance and a remarkable heterogeneity among different populations. Most often they are polygenic and several genetic loci have been linked with the risk of developing autoimmune diseases. However, causal inference is difficult. When the genomic revolution began there were high hopes of translating fast genetic analyses to the bedside but this has proven to be challenging. Nonetheless, over the last decade, fine-mapping strategies have greatly improved; one of the most significant research lines focuses on the in vivo and ex vivo definition of the effect of genetic variants within the target tissues and within specific subpopulations of immune cells that are involved in the disease pathogenesis. This strategy also includes the longitudinal tracking of a large number of immunophenotypes in many individuals to build a large reference atlas for variant characterization. In this review, we discuss the results obtained by GWAS in autoimmune diseases and review recent advances in fine mapping strategies. More importantly, we discuss gaps and future directions.
Articolo in rivista - Review Essay
Autoimmunity; eQTL; Fine mapping; Genetic variants; GWAS; Liver;
English
7-ott-2022
2022
133
December 2022
102922
none
Gerussi, A., Soskic, B., Asselta, R., Invernizzi, P., Gershwin, M. (2022). GWAS and autoimmunity: What have we learned and what next. JOURNAL OF AUTOIMMUNITY, 133(December 2022) [10.1016/j.jaut.2022.102922].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/395920
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact